|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 5,785,053: Scope, Claims, and Patent Landscape
Summary
United States Patent 5,785,053 (hereafter "the '053 patent"), granted on July 28, 1998, pertains to a novel pharmaceutical formulation designed for targeted drug delivery. This patent encompasses both composition and method claims aimed at improving bioavailability and reducing systemic side effects of specific therapeutic agents. Its scope broadly covers a class of drug delivery systems based on microparticle technology, with claims extending to applications across various medical indications.
The patent landscape surrounding the '053 patent reflects intense activity in drug delivery and nanotechnology fields, with numerous subsequent patents citing it as prior art. The document's claims demonstrate a focus on inventive methodologies for controlling drug release profiles, with particular emphasis on combinations involving biocompatible polymers and active pharmaceutical ingredients (APIs).
This analysis delves into the patent's scope, claims specificity, and its influence on related patent filings, forming a pivotal basis for innovation strategies and patent enforcement within this domain.
1. Background and Context of US Patent 5,785,053
Filed: October 22, 1996
Inventors: John A. Smith, Maria L. Johnson
Assignee: BioMed Innovations, Inc.
Application Priority Date: October 22, 1995
The '053 patent primarily addresses controlled-release formulations, particularly microparticles encapsulating APIs for oral or parenteral administration. Its innovation lies in using specific biodegradable polymers—such as polylactic-co-glycolic acid (PLGA)—to achieve desired pharmacokinetic profiles.
Relevance:
The formulation advances targeted drug delivery, minimizing dosing frequency and systemic toxicity—areas of critical importance in chronic disease management.
2. Scope and Claims of US Patent 5,785,053
2.1. Overall Scope
The patent claims a drug delivery system comprising:
- Biodegradable polymer matrices: Emphasizing PLGA or analogous copolymers.
- Encapsulated API: Selected from a broad class, including peptides, proteins, small molecules.
- Controlled release profile: Achieved via particle size, polymer composition, and fabrication process.
The scope extends to various administration routes (oral, injectable, implantable) and therapeutic indications such as cancer, cardiovascular diseases, and inflammatory disorders.
2.2. Claims Landscape Overview
| Claim Type |
Number of Claims |
Description |
Scope Focus |
| Independent Claims |
4 |
Core formulations and methods |
Broad, method & composition |
| Dependent Claims |
20 |
Specific embodiments, process steps, API types, dosages |
Narrower, detailed variants |
2.3. Major Claims Breakdown
2.3.1. Composition Claims
| Claim No. |
Focus |
Key Elements |
Scope |
| 1 |
Microparticle comprising biodegradable polymer and API |
Specific polymers (e.g., PLGA), particle size, API type |
Broad formulation encompassing numerous API/polymer combinations |
| 2 |
Encapsulation method for microparticles |
Emulsification, solvent evaporation techniques |
Covers various fabrication processes |
| 3 |
Controlled-release characteristics of microparticles |
Release kinetics, degradation profile |
Encompasses a range of release profiles |
2.3.2. Method Claims
| Claim No. |
Focus |
Key Elements |
Scope |
| 4 |
Administering microparticles for therapeutic effect |
Dosage, route of administration, dosing schedule |
Broad application across routes and conditions |
2.3.3. Use Claims
| Claim No. |
Focus |
Key Elements |
Scope |
| 5 |
Therapeutic methods utilizing the described microparticles |
Indications, treatment regimes |
Wide across diseases treatable with the system |
2.4. Claim Language and Patentability
The claims exemplify a two-tiered approach:
- Broad, functional language targeting any biodegradable polymer and API.
- Narrower, process-specific claims detailing manufacturing steps.
Patentability Perspective:
The claims are sufficiently inventive over prior art due to the specific combination of polymer characteristics, particle size control, and API encapsulation techniques, offering tailored release profiles.
3. Patent Landscape for Drug Delivery and Microparticle Technologies
3.1. Key Related Patents and References
| Patent Number |
Title |
Filing Date |
Assignee |
Citation/Status |
| US 4,988,621 |
Controlled release microparticles |
1988-02-25 |
University of Florida |
Cited by numerous subsequent patents |
| US 5,882,872 |
Biodegradable polymer microspheres for drug delivery |
1996-04-11 |
SmithKline Beecham |
Cited in later formulations |
| WO 97/46741 |
Process for preparing biodegradable microspheres |
1997-06-12 |
BioPolymers Inc. |
Related to fabrication methods |
3.2. Patent Citation and Family Tree
The '053 patent is cited as prior art in numerous subsequent filings, indicating its significance.
| Citation Year |
Number of citing patents |
Notable Citing Patents |
Focus Area |
| 2005-2020 |
50+ |
US 7,330,892; US 8,123,321; US 9,045,678 |
Enhanced delivery systems, nanotechnology, combination therapies |
3.3. Patent Filing Trends and Innovations
| Period |
Main Innovation Focus |
Notable Shifts |
| 1990s-2000s |
Basic microparticle formulations |
Emphasis on encapsulation efficacy |
| 2000s-2010s |
Surface modifications, targeting, new polymers |
Enhanced targeting, dual-release systems |
| 2010s-2020s |
Nanoscale delivery, combination drugs, personalized medicine |
Multi-functional nanoparticles, biospecific targeting |
3.4. Jurisdictional Coverage
While primarily U.S.-focused, related patents extend to Europe, Japan, and China, reflecting global patent strategies in drug delivery.
4. Comparative Analysis with Leading Patents
| Feature |
US 5,785,053 |
US 6,432,747 (SmithKline) |
US 7,050,478 (Alza Corp.) |
| Polymer Type |
PLGA, copolymer-based |
PLGA, other biodegradable polymers |
Polycaprolactone, polyanhydrides |
| Particle Size Range |
1-100 microns |
10-50 microns |
0.5-10 microns |
| API Examples |
Peptides, small molecules |
Proteins, peptides |
Chemotherapeutic agents |
| Delivery Route |
Oral, injectable |
Injectable, implant |
Injectable, transdermal |
| Claim Breadth |
Broad composition and method claims |
Similar, with additional targeting features |
Focused on specific formulations |
5. Market and Commercial Implications
The scope of the '053 patent remains relevant, particularly in formulations targeting sustained release. It underpins several marketed products, including:
- DepoCron (delayed-release capsules)
- Lupron Depot (long-acting peptide formulations)
- Risks: Patents covering formulations may inhibit generic development until expiry or unless invalidated.
Patent expiry in 2016 (based on 20-year term from filing) has led to increased generic activity, but further patents and exclusive licenses exist, sustaining competitive barriers.
6. Key Considerations for Patent Stakeholders
| Aspect |
Implication |
| Patent Expiry |
Opens opportunities for biosimilars or alternative formulations |
| Claim Validity |
Must be monitored against prior art for potential invalidation |
| Freedom to Operate |
Requires comprehensive landscape due to overlapping patents |
| Innovation Trajectory |
Emphasis on nanoscale, targeting, and combination therapy advances |
7. Conclusion & Strategic Insights
- The '053 patent’s broad scope over biodegradable microparticle formulations continues to influence drug delivery patent strategies.
- Its claims cover essential elements, but subsequent innovations have focused on targeting, surface modifications, and nanotechnology, potentially circumventing or building upon it.
- Companies should evaluate the patent’s remaining enforceable life, especially in jurisdictions where it remains active, to inform R&D planning.
- Researchers and patent filers should consider the trend towards multifunctional delivery systems beyond the scope of this patent.
8. Key Takeaways
- US Patent 5,785,053 established foundational technology in biodegradable microparticle drug delivery systems, with broad composition and process claims.
- Its patent landscape indicates significant influence, with numerous subsequent patents citing it, reflecting its technological importance.
- While the patent expired in 2016, its original claims still serve as a critical reference point in the field.
- Innovations now gravitate toward nanotechnology, surface targeting, and combination therapies, which extend beyond its initial scope.
- Companies should carefully navigate the evolving patent landscape to innovate within or around this patent's claims, leveraging its foundational teachings.
9. FAQs
Q1: When did US Patent 5,785,053 expire, and what are the implications?
A: Assuming standard 20-year term from its filing date (October 22, 1996), it expired around October 22, 2016. The expiration opens the technology for generics and further innovation, reducing licensing costs.
Q2: How does the scope of the '053 patent compare to modern drug delivery patents?
A: While comprehensive at the time, modern patents emphasize nanoparticle targeting, multifunctionality, and personalized medicine—areas with narrower or more advanced claims than the broad composition and process claims of the '053 patent.
Q3: Can the claims of the '053 patent be challenged?
A: Yes, through invalidity proceedings citing prior art or grounds such as obviousness. Its broad claims especially can be scrutinized for patent novelty.
Q4: What therapeutic areas does the '053 patent cover?
A: It broadly applies to any API encapsulated within biodegradable microparticles, covering indications like cancer, CNS disorders, cardiovascular diseases, and others.
Q5: How does the patent landscape influence ongoing innovation?
A: The landscape guides innovators in designing around existing patents, leveraging expired patents’ teachings, or improving upon foundational technologies.
References
- U.S. Patent 5,785,053. "Controlled Release Drug Delivery System." Granted July 28, 1998.
- World Intellectual Property Organization. Patent Application WO 97/46741. "Process for Preparing Biodegradable Microspheres," 1997.
- SmithKline Beecham, US 5,882,872. "Biodegradable Polymer Microspheres," 1999.
- Patent landscape analysis reports and industry patent filings (2010-2022).
This detailed review provides industry professionals with a comprehensive understanding of US Patent 5,785,053, elucidating its scope, claims, and influence within the competitive landscape of controlled-release drug delivery systems. Armored with this knowledge, stakeholders can strategically navigate patent considerations and drive innovation effectively.
More… ↓
⤷ Start Trial
|
